Storm Therapeutics raised $56 million in a Series C to fund phase II development of STC-15, an RNA enzyme inhibitor targeting METTL3-driven methylation pathways in selected sarcoma subtypes. The company also said the first patient has been treated in the phase II trial, with the program targeting myo- and liposarcomas. The financing positions Storm to generate phase II readouts across multiple indications where targeted options remain limited and conventional immunotherapy has underperformed for many patients. In communications around the round, Storm framed STC-15’s mechanism as a way to reprogram malignant cells toward cell-cycle arrest and apoptosis. For investors and pipeline watchers, the update reinforces interest in RNA-modifying enzymes as druggable drivers and in moving fast from early clinical signals to proof-of-concept in homogeneous sarcoma populations.